Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer-Reference-Cited by-全球学者库

Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer

Published:2023-08-10 Issue:6 Volume:389 Page:491-503
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Wakelee Heather¹,Liberman Moishe¹,Kato Terufumi¹,Tsuboi Masahiro¹,Lee Se-Hoon¹,Gao Shugeng¹,Chen Ke-Neng¹,Dooms Christophe¹,Majem Margarita¹,Eigendorff Ekkehard¹,Martinengo Gastón L.¹,Bylicki Olivier¹,Rodríguez-Abreu Delvys¹,Chaft Jamie E.¹,Novello Silvia¹,Yang Jing¹,Keller Steven M.¹,Samkari Ayman¹,Spicer Jonathan D.¹

Affiliation:

1. From Stanford University School of Medicine, Stanford Cancer Institute, Stanford, CA (H.W.); Centre Hospitalier de l’Université de Montréal (M.L.) and McGill University Health Centre (J.D.S.) — both in Montreal; Kanagawa Cancer Center, Yokohama (T.K.), and National Cancer Center Hospital East, Kashiwa (M.T.) — both in Japan; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea (S.-H.L.); the National Cancer Center, National Clinical Research Center for Cancer, Cancer...

Funder

Merck Sharp and Dohme LLC, a subsidiary of Merck & Co, Inc

National Cancer Institute

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2302983

Reference19 articles.

1. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

2. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer